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SUMMARY 
A pharmacokinetic study was done on 10 depressed patiants (DSM-III-R 296.3). The patients 
were treated with Sintamil (R) (nitroxazepine. HC1) with titrated dose from 75 mg to 225 mg for 6 
weeks. Plasma level? of nitroxazepine (Sintamil (R)) and its metabolites desmethyl (D), N-oxide (N-O) 
and carboxylic acid (c) were estimated. Anti-depressant efficacy was judged by reduction in Hamilton 
Rating Depression Scale (HDRS) scores, and tolerability was monitored by reports of unwanted 
effects. 
The overall reduction in HDRS score was about 50% by 6 weeks. The plasma levels of nitroxa-
zepin (ng/ral) showed a rise from a mean ( fSEM) level. 47.0 4-7.3 on day 1 (dose 75 mg) to 129.84-24.6 
on day 7 (dose 150 mg) (p<0.01) and remained steady till day 21. There were large interindividual 
variations. The metabolites followed a similar pattern. The HDRS score showed a steady reduction 
between day 14 and 42 when the levels of nitroxizepine and des-methyl metabolites were maintained 
between 176.5 ng/ml to 251 ng/ml. 
In recent years, therapeutic drug 
monitoring (TDM) of tricyclic antidepres-
sant (TGAs) has been recommended for 
several therapeutic situations (Preston et 
al., 1988; De-Oliveira et a)., 1989). Be-
sides the use of TDM in monitoring com-
pliance and avoiding toxicity in high risk 
groups c. g. elderly, cardiac illness, ii has 
also been recommended to maximise 
clinic.il response (Preston et al., 1988; 
De-Oliveira et a!., 1989). In order to 
useitroutinely.it is necessary to define 
the plasrm levels at different dosage of 
TGAs and to correlate them with clinical 
response. However, it is difficult to ex-
trapolate the western data to any popu-
lation because of genetic variation in 
metabolism of TGAs (Preston et al., 1988; 
Dc Oliveria ct al., 1989). Hence, even 
with well known drugs, it is necessary to 
study their pharmacokinetics in a popula-
tion where the drug is newly introduced 
(Bhatiact al., 1988). 
Nitroxazepine hydrochloride (Sin-
tamil (R) was introduced in India in 
1982. Howevere, its kinetics and meta-
bolism in depressed patients could not be 
studied during the early clinical studies 
due to lack of availability of modern ana-
lytical techniques e. g. gas-chromotogra-
phy, high preformance liguid chxomo-
tography (Sheth et al., 1972). A limi-
ted study in healthy volunteers with radio 
labelled nitroxazepine in low doses (25 
mg) suggested that drug metabolised 
differently as compared to animals. 
(Sheth etal., 1972). Since there were 
no kinetic data with doses in therapeutic 
range 75 mg to 225 mg, the present 
study was planned to estimate plasma 
levels of nitroxazepine and its metabolites 
and to judge whether any relationship 
could be seen between the plasma levels 
and antidepressant activity. 
Materials and methods 
Adult patients suffering from major 
depressive disorder (DSM-III-R 296.3) 
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with a minimum score of 17 on Hamilton 
Depression Rating Scale (HDRS) were 
included in the study. Those who were 
already on antidepressants were included 
after withdrawing the drugs for atleast 2 
weeks. Patients who were chronic heavy 
smokers, or alcohol drinkers or were 
suffering from severe systemic disease e. g. 
renal failure, liver dysfunction or pre-
gnant women were excluded from the 
study. Informed consent was obtained 
from each patient. 
After an assessment of cardiovascular 
and other systemic status, they were hos-
pitalised for 3 weeks and put on nitroxa-
zepine HC1 (Sintamil R) 75 mg and dose 
was titrated upto 100 mg once daily by 
day 4 and 150 mg once daily by day 7. If 
on day 13, HDRS score showed a reduc-
tion >50%, the drug was continued in a 
dose of 150 mg once daily from day 14 to 
day 42. If the HDRS score showed a re-
duction <50%, the dose of nitroxazepine 
HGI was raised to 225 mg (150 mg 
morning + 75 mg night) on day 14 and 
maintained upto day 42. The dose titra-
tion was done without waiting for the 
pharmacokinetic data. 
Blood was also collected on days 1, 
4, 7, 14, 21, 28, 35, 42 before drug and 2 
hours after drug administration for esti-
mation of drug levels. Nitroxazepine HGI 
(N) and its Desmethyl (D) and N-oxide 
(N-O) metabolite were measured in 
plamsa by a normal-phase High Pressure 
Liquid Chromatography (HPLG) using 
standard solutions. The solutions were 
prepared by dissolving pure substances of 
N,D and N-O in 50 ml methanol and 
diluted to give concentrations of 1-2 meg/ 
ml. For estimation of Garboxylic acid 
(G) metabolite a. reverse-phase HPLC 
was employed with indomethacin (MSD) 
as internal standard. The equipment was 
Model 5000 liquid chromatograph (Vari-
an USA) with a spectromonitor D varia-
ble wavelength detector (LDC/Milton 
Roy) and a Model 7125 syringe loading 
sample injector (Rheodyne USA). The 
detection was done at 266 nm and the 
signal was monitored on a chromatopac 
C-R 3A (Shinadzu Japan) electronic 
integrator at an attenuation of 3 or 4 and 
a chart speed of 0-5 cm/min. Patients 
were not allowed to take any other drugs 
which could affect plasma levels of nitro-
xazepine and its metabolites. Plasma 
levels on different doses were compared 
by students paired
 £t' test. 
The tolerability of nitroxazepine was 
judged by monitoring of baseline com-
plaints, reports of unwanted effects mea-
surement of pulse and blood pressure, 
records of ECG and assessment of hae-
matological and liver functions. The 
above variables were assessed before drug 
and after drug on days 14, 28 and 42. 
Results 
Ten patients (male 6, female 4) par-
ticipated in the study. 
The mean pre-drug HDRS was 31.2 
and it dropped to 15.5 (50 % reduction) 
by day 42. As none of the patients 
showed >50% reduction in HDRS by 
day 13, all of them received 225 mg of 
nitroxazepine between day 14 and 42 
for 4 weeks. 
Plasma Levels of Nitroxazepine and its Me-
tabolites [Table-J) 
As there were large variations in 
0 hr. values of plasma levels of N and 
its metabolites, only 2 hour values have 
been included in the analysis. The 
plasma levels of N showed a significant 
rise (p<0.01) from a mean level of 47.0 
mg/ml on day 1 (dose 75 mg) to 129.8 
mg/ml on day 7 (dose 150 mg) and re-
mained fairly steady till day 21 and drop-
ped to 97.0 ng/ml by day 42. Metobo-
lite D also showed an increase from 29.6 
ng/ml on day 1 to 62.1 ng/ml on day 7 
(p<0.01) and showed a similar pattern 138  A.D. BHATT it at. 
TABLE 1—Plasma Levels (ngjml.) of NUroxayepine and its Metabolites in Patients (jV*=10) 
(Mean+SEM) 
Day 
1 
4 
7 
14 
21 
28 
35 
42 
Nitroxazepine 
47.0+7.3 
53.4+14-9 
129.8+24.6 
117.5+25.4 
132.8+14.7 
KIG.0+28.9 
96.3+ 19-1 
97-0+18.7 
Desmethyl 
29.6 + 3.1 
42.4+5.9 
62.1+8.7 
75.1+10.5 
118.5+13.8 
93.5+ 13.9 
86.9+9.1 
79.4+8.6 
N-O 
40+3.3 
43.0+6.3 
68.6+15.7 
70.6 + 15.7 
86.9 + 8.4 
61-6+14.2 
61.7+15.6 
60.9+14.0 
Carboxylic acid 
398.9+-45-4 
474.9+83.7 
577-9+94.9 
560.7 + 90.5 
770.2 + 86.9 
472-7 + 80.6 
602-2 + 97.3 
617.0+102.1 
thereafter, N-O and C metabolite also 
showed a significant rise by day 7 
(p<0.05). There were large inter indi-
vidual variations in the plasma levels. 
However, there was no significant differe-
nce between the levels of N and its meta-
bolites on day 21,28,33 and 42. 
Relation between efficacy and plasma 
levels 
It was dilficult to correlate the HD-
RS reduction and plasma levels because 
of small number of patients and large 
interiudividu.il variations. However, un-
til day 13 when the dose titration was up-
to 150 rag reduction in UDRS was 19.7%. 
Later on, the MORS scores dropped 
steadily over 4 weeks when steady levels 
of N and its metabolites were maintai-
ned. 
ToUrabilily of .Sit'oxazepine 
The drug was well tolerated and 
there were no drop-outs due to severe 
unwanted effects. The heart rate did 
not show any significant alterations. The 
supine and standing!). P. did not show 
any orthostatic hypotension even at a dose 
of 150 nig and above. There was no 
significant change in PR, QRS and QTC 
intervals on EGGs taken after nitroxa-
zepine. Haematological and liver func-
tions before and after N did not show 
any significant abnormalities. 
Discussion 
The present study showed that nitro-
xazcpine is an effective antidepressant 
showing a reduction of 50% in HDRS 
score. The drug was well absorbed in 
depressed patients and showed a dose 
dependent rise in plasma levels. The 
plasma levels were comparable to those 
observed in healthy volunteers with 
single dose of nitroxazepine of 75 and 
150 mg. (Bhatia ct al., 1988). The 
plasma levels on nirtroxazepine 150mg 
were about twice as high as on 75 mg 
(p^O.Ol). Nitroxazepine was metaboli-
sed extensively and showed rising levels 
of desmethyl, N-oxidc and carboxylic 
acid metabolites over a period of 6 
weeks. 
The plasma levels of nitroxazepine 
and its metabolites showed a high interin-
dividual variation. The variation h 
similar to that observed with other TGAs 
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plasma levels (Preston et al.} 1988; De 
Oliveira et al., 1989) and could be due 
to differences in metabolism of TGAs. 
The total level of nitroxazepine andits 
metabolite desmethly are in the range of 
176.5 ng/ml to 251 ng/mg (meg/1) at 
the optimum and commonly used effec-
tive dose »f 150 mg. There are relatively 
less number of studies of TGAs levels in 
Indian patients. However, the range of 
levels of N and D is comparable to the 
therapeutic levels of imipram'ne and 
desimipraminc of between 150 to 300 
meg (Preston et al., 1983; De Oliveira 
et al., 1988). At the optimum dose of 
150 mg, the HDR.S score also showed 
improvement suggesting that these levels 
are necessary for optimum therapeutic 
response. 
The study also suggested that HL>RS 
scores are reduced by a single dose of 
nitroxazepine. Although, nitroxazepine 
has a short plasma half-life, the metabo-
lites, desmethyl and carboxylic acid have 
long half-life of 8 and 15 hours respec-
tively (Bhatia et al., 1988). Animal 
studies have shown that all the metabo-
lites desmethyl, N-oxide and carboxylic 
have antidepressant activity (Nagarajan, 
1972). It appears that the antidepressant 
activity seen with a single dose of drug 
is not only due to nitroxazepine but also 
due to its metabolites. It may be neces-
sary to measure all the metabolites while 
judging therapeutic levels. 
In conclusion, the present study has 
shown that nitroxozepine is well absorbed 
and metabolised in depressed patients 
into active metabolites. The doses of 
150 mg and beyond, show plasma levels 
comparable to therapeutic levels with 
other TCAs and also show antidepressant 
efficacy. As suggested for other TCA
;, 
rapid titration of nitroxazepine dose to 
150 mg might improve efficacy (Pres-
ton ct al., 1988; De Oliveira et al, 
1989). However this needs to be confir-
med by a special clinical and pharma-
cokinetic study incorporating rapid titra-
tion of dose based on plasma levels of 
nitroxazepine and its metabolites. 
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